ArticleJournal of endocrinological investigation2022
Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
Article in Journal of endocrinological investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves' orbitopathy.European thyroid journal · 2025Review
- Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimus.Journal of endocrinological investigation · 2025Article
- Long-term outcome of Graves' orbitopathy following treatment with sirolimus.Journal of endocrinological investigation · 2025Article
- Graves disease: latest understanding of pathogenesis and treatment options.Nature reviews. Endocrinology · 2024Review
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.International journal of clinical pharmacy · 2024Article
- Article
- Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets.Journal of clinical medicine · 2023Review
- Teprotumumab in thyroid eye disease: wonder drug or great divider?European thyroid journal · 2023Article
- Traditional Chinese medicine in thyroid-associated orbitopathy.Journal of endocrinological investigation · 2023Review
- Prostaglandin F2α Regulates Adipogenesis by Modulating Extracellular Signal-Regulated Kinase Signaling in Graves' Ophthalmopathy.International journal of molecular sciences · 2023Article
- Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.International ophthalmology · 2023Review
- Teprotumumab-Related Hyperglycemia.The Journal of clinical endocrinology and metabolism · 2023Observational
- Emerging therapies in the medical management of thyroid eye disease.Frontiers in ophthalmology · 2023Review
- Role of teprotumumab in the treatment of active moderate-to-severe Graves' orbitopathy.European thyroid journal · 2022Article
- Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association.European thyroid journal · 2022Article
- Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.Thyroid : official journal of the American Thyroid Association · 2022Article
- Current concepts regarding Graves' orbitopathy.Journal of internal medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.